Figure 4

Overall survival in the patient group of >90% ERα positive, cyclin D1 high breast cancers subdivided according to tamoxifen treatment or no treatment with indication of a calculated expected survival for an aged-matched non-breast cancer cohort. P-values are presented in a box with value at 10 years of follow-up (22 years of follow-up in parenthesis).